⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
India has one of the highest burdens of thyroid disease in the world. An estimated 42 million Indians have thyroid disorders, with hypothyroidism — an underactive thyroid — being the most common. Given that hypothyroidism causes weight gain and makes weight loss difficult, a large proportion of GLP-1 medication users in India also have thyroid disease.
If you have hypothyroidism and are considering or currently using semaglutide (Ozempic, Rybelsus) or tirzepatide (Mounjaro), this guide covers everything you need to know.
Consult your healthcare provider before starting any medication. This article is informational only.
The thyroid gland produces hormones (primarily T4 and T3) that regulate metabolic rate — the speed at which your body burns energy. When the thyroid is underactive:
This is why weight loss is extremely difficult in uncontrolled hypothyroidism — even with diet and exercise. GLP-1 medications have become an important tool for thyroid patients who, despite adequate levothyroxine therapy, still struggle to lose weight.
For hypothyroidism specifically: yes, GLP-1 medications are generally safe and may actually be beneficial. Research shows GLP-1 medications improve insulin sensitivity (which hypothyroid patients often have reduced), reduce systemic inflammation (beneficial for autoimmune thyroiditis/Hashimoto's), and support weight loss even in a slower metabolic state.
However, there is one important caution:
Animal studies found that GLP-1 receptor agonists caused C-cell tumours (medullary thyroid carcinoma, or MTC) in rodents at high doses over prolonged periods.
What this means for humans:
This warning does NOT apply to common hypothyroidism, Hashimoto's thyroiditis, or papillary/follicular thyroid cancer. Only MTC and MEN2 are contraindications.
Before starting GLP-1 medications, tell your doctor about any personal or family history of thyroid cancer.
This is the most practically important issue for Indian patients on both medications:
Levothyroxine (Eltroxin, Thyronorm) must be taken:
Rybelsus (oral semaglutide) must also be taken:
You cannot take both at the same time. Practical solution:
For injectable semaglutide (Ozempic) or tirzepatide (Mounjaro): Weekly injections do not interact with levothyroxine absorption and are generally simpler to manage.
Starting GLP-1 therapy sometimes "unmasks" previously undiagnosed subclinical hypothyroidism. Watch for:
If you notice these symptoms, ask your doctor to test TSH — even if your thyroid was previously normal.
As you lose weight on GLP-1 therapy, your levothyroxine dose may need adjustment. Levothyroxine dosing is based on body weight (approximately 1.6-1.8 mcg per kg). If you lose 10-15kg, your ideal dose drops proportionally. Continuing the same dose can cause mild hyperthyroidism with symptoms like palpitations, anxiety, and excessive sweating.
Tell your doctor whenever your weight changes by more than 5kg so they can recheck your TSH and adjust the dose.
Before starting:
During therapy:
If weight loss stalls despite good compliance:
Taking levothyroxine and Rybelsus within minutes of each other. Both require an empty stomach — space them by at least 30-45 minutes.
Not telling your endocrinologist you are on GLP-1. Both drugs need ongoing monitoring and ideally a coordinated care approach.
Assuming thyroid tests are fine because they were normal last year. Significant weight loss changes your thyroid hormone requirements. 6-monthly testing is recommended while on GLP-1.
Stopping levothyroxine hoping GLP-1 will fix your thyroid. GLP-1 does not treat thyroid hormone deficiency. Discontinuing levothyroxine without medical supervision is dangerous.
Q: My TSH is 3.5 — my doctor says it is normal but I am losing very little weight on GLP-1. Could my thyroid be the problem? Possibly. Emerging evidence suggests TSH above 2.5 mIU/L is associated with lower metabolic rate and slower weight loss. Some endocrinologists recommend targeting TSH of 0.5-2.0 mIU/L for active weight management. Discuss levothyroxine dose optimisation with your doctor.
Q: I have Hashimoto's thyroiditis — is GLP-1 safe? Yes. Hashimoto's is not a contraindication to GLP-1 therapy. GLP-1 medications have anti-inflammatory properties that may be particularly beneficial for autoimmune thyroid conditions.
Q: Can GLP-1 medications improve my thyroid function? Indirectly, yes. Weight loss reduces metabolic burden on the thyroid, and reduced inflammation may benefit autoimmune thyroid conditions. However, GLP-1 does not replace thyroid hormone supplementation.
Q: I had my thyroid removed due to cancer. Can I take GLP-1? For papillary or follicular thyroid cancer: generally yes. For medullary thyroid carcinoma specifically: GLP-1 medications carry a contraindication warning. You must discuss this with your oncologist and endocrinologist.
This article is for informational purposes only. Always consult a qualified endocrinologist or physician before starting GLP-1 medications if you have thyroid disease.
